Akari Therapeutics PLC (NASDAQ:AKTX)’s share price crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.00 and traded as low as $2.03. Akari Therapeutics shares last traded at $2.03, with a volume of 500 shares traded.
Several equities research analysts have recently issued reports on AKTX shares. ValuEngine raised shares of Akari Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, March 14th. B. Riley set a $7.00 price objective on shares of Akari Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, March 19th. Finally, Zacks Investment Research raised shares of Akari Therapeutics from a “hold” rating to a “buy” rating and set a $4.50 price objective for the company in a research report on Friday, April 26th.
The company has a 50-day simple moving average of $2.34. The firm has a market capitalization of $31.88 million, a P/E ratio of -12.18 and a beta of -2.89.
Akari Therapeutics (NASDAQ:AKTX) last released its quarterly earnings results on Wednesday, May 29th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter. On average, sell-side analysts predict that Akari Therapeutics PLC will post -1 EPS for the current fiscal year.
A hedge fund recently bought a new stake in Akari Therapeutics stock. Virtu Financial LLC acquired a new position in shares of Akari Therapeutics PLC (NASDAQ:AKTX) in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 39,864 shares of the biopharmaceutical company’s stock, valued at approximately $143,000. Virtu Financial LLC owned approximately 0.26% of Akari Therapeutics at the end of the most recent reporting period. 14.90% of the stock is owned by hedge funds and other institutional investors.
About Akari Therapeutics (NASDAQ:AKTX)
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases. Its lead drug candidate is Coversin, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, and atypical hemolytic uremic syndrome.
Further Reading: Green Investing
Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.